Head to Head Contrast: Sintx Technologies (NASDAQ:SINT) and Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS) and Sintx Technologies (NASDAQ:SINT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Valuation and Earnings

This table compares Bioventus and Sintx Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09 million	1.94	$22.73 million	$0.77	17.05
Sintx Technologies	$1.08 million	8.80	-$10.36 million	($4.91)	-0.45

Bioventus has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bioventus and Sintx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Sintx Technologies	-848.20%	-354.44%	-115.37%

Analyst Ratings

This is a summary of current ratings and target prices for Bioventus and Sintx Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	5	0	2.83
Sintx Technologies	1	0	3	0	2.50

Bioventus presently has a consensus price target of $16.80, indicating a potential upside of 27.95%. Sintx Technologies has a consensus price target of $9.50, indicating a potential upside of 329.86%. Given Sintx Technologies’ higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Bioventus.

Insider & Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Bioventus beats Sintx Technologies on 11 of the 13 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.